Based on the Phio Pharmaceuticals Corp stock forecast from 1 analysts, the average analyst target price for Phio Pharmaceuticals Corp is USD 4.00 over the next 12 months. Phio Pharmaceuticals Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Phio Pharmaceuticals Corp is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Phio Pharmaceuticals Corp’s stock price was USD 1.03. Phio Pharmaceuticals Corp’s stock price has changed by -20.77% over the past week, -20.77% over the past month and -83.17% over the last year.
No recent analyst target price found for Phio Pharmaceuticals Corp
No recent average analyst rating found for Phio Pharmaceuticals Corp
Company Overview Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. Read Less
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that in...Read More
Frequently Asked Questions About Phio Pharmaceuticals Corp (PHIO) Stock
Based on ratings from 1 analysts Phio Pharmaceuticals Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on PHIO's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for PHIO is USD 4.00 over the next 12 months. The maximum analyst target price is USD 4 while the minimum anlayst target price is USD 4.
PHIO stock's Price/Earning ratio is 0.01.
Our analysis grades PHIO stock's Price / Earning ratio at A-. This means that PHIO stock's Price/Earning ratio is above 8.999999999999996% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this PHIO may be undervalued for its sector.
The last closing price of PHIO's stock was USD 1.03.
The most recent market capitalization for PHIO is USD 2.02M.
Based on targets from 1 analysts, the average taret price for PHIO is projected at USD 4.00 over the next 12 months.
This means that PHIO's stock price may go up by +296.04% over the next 12 months.
We can't find any ETFs which contains Phio Pharmaceuticals Corp's stock.
As per our most recent records Phio Pharmaceuticals Corp has 8 Employees.
Phio Pharmaceuticals Corp's registered address is 11 Apex Drive, Marlborough, MA, United States, 01752.
You can get more information about it from Phio Pharmaceuticals Corp's website at https://phiopharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Phio Pharmaceuticals Corp (PHIO) Stock
Based on ratings from 1 analysts Phio Pharmaceuticals Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on PHIO's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for PHIO is USD 4.00 over the next 12 months. The maximum analyst target price is USD 4 while the minimum anlayst target price is USD 4.
PHIO stock's Price/Earning ratio is 0.01.
Our analysis grades PHIO stock's Price / Earning ratio at A-. This means that PHIO stock's Price/Earning ratio is above 8.999999999999996% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this PHIO may be undervalued for its sector.
The last closing price of PHIO's stock was USD 1.03.
The most recent market capitalization for PHIO is USD 2.02M.
Based on targets from 1 analysts, the average taret price for PHIO is projected at USD 4.00 over the next 12 months.
This means that PHIO's stock price may go up by +296.04% over the next 12 months.
We can't find any ETFs which contains Phio Pharmaceuticals Corp's stock.
As per our most recent records Phio Pharmaceuticals Corp has 8 Employees.
Phio Pharmaceuticals Corp's registered address is 11 Apex Drive, Marlborough, MA, United States, 01752.
You can get more information about it from Phio Pharmaceuticals Corp's website at https://phiopharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PHIO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
